What was CSL’s turnaround plan and why did investors dislike it?

Health editor Michael Smith discusses CSL’s remarkable story, why investors have lost faith in the healthcare giant and what Trump has to do with it.

This podcast is sponsored by Aussie Broadband

Further reading:

How CSL went from 'bloated bureaucracy' to $145b global behemoth
When Brian McNamee took on the top job at Commonwealth Serum Laboratories, the government-run entity was barely worth the land it was built on.
McNamee vows to stay CSL chairman despite growing investor disquiet
The pharmaceutical giant has avoided a board spill, but a market bloodbath arising from declining US vaccine rates has investors seething.
‘We have to fix this’: Brian McNamee on turning around CSL
CSL was once a market darling, now it’s out of favour and pressure is on board and management to convince sceptical investors of a plan to restructure the business.

See omnystudio.com/listener for privacy information.